Cerity Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $37.7M | Buy |
270,352
+26
| +0% | +$3.64K | 0.05% | 294 |
|
|
2025
Q4 | $33.2M | Buy |
270,326
+19,673
| +8% | +$2.39M | 0.05% | 302 |
|
|
2025
Q3 | $27.8M | Buy |
250,653
+4,863
| +2% | +$553K | 0.05% | 317 |
|
|
2025
Q2 | $27.3M | Sell |
245,790
-8,230
| -3% | -$876K | 0.05% | 308 |
|
|
2025
Q1 | $28.5M | Buy |
254,020
+82,179
| +48% | +$8.48M | 0.06% | 269 |
|
|
2024
Q4 | $15.4M | Sell |
171,841
-82,031
| -32% | -$7.39M | 0.03% | 377 |
|
|
2024
Q3 | $21.3M | Buy |
253,872
+49,604
| +24% | +$3.79M | 0.05% | 305 |
|
|
2024
Q2 | $14M | Buy |
204,268
+28,785
| +16% | +$1.92M | 0.04% | 342 |
|
|
2024
Q1 | $12.8M | Buy |
175,483
+28,743
| +20% | +$2.21M | 0.03% | 394 |
|
|
2023
Q4 | $11.9M | Buy |
146,740
+74,249
| +102% | +$5.78M | 0.04% | 338 |
|
|
2023
Q3 | $5.43M | Sell |
72,491
-63,723
| -47% | -$4.9M | 0.03% | 404 |
|
|
2023
Q2 | $10.5M | Buy |
136,214
+31,841
| +31% | +$2.54M | 0.04% | 336 |
|
|
2023
Q1 | $13.2M | Sell |
104,373
-1,911
| -2% | -$158K | 0.03% | 314 |
|
|
2022
Q4 | $9.43M | Buy |
106,284
+14,217
| +15% | +$1.13M | 0.06% | 275 |
|
|
2022
Q3 | $5.68M | Buy |
92,067
+2,380
| +3% | +$150K | 0.07% | 221 |
|
|
2022
Q2 | $5.54M | Buy |
89,687
+20,391
| +29% | +$1.26M | 0.06% | 235 |
|
|
2022
Q1 | $4.12M | Sell |
69,296
-4,875
| -7% | -$312K | 0.06% | 217 |
|
|
2021
Q4 | $5.39M | Buy |
74,171
+9,952
| +15% | +$685K | 0.08% | 192 |
|
|
2021
Q3 | $4.49M | Sell |
64,219
-2,293
| -3% | -$161K | 0.1% | 170 |
|
|
2021
Q2 | $4.58M | Sell |
66,512
-12,903
| -16% | -$862K | 0.1% | 165 |
|
|
2021
Q1 | $5.13M | Sell |
79,415
-237
| -0.3% | -$15.3K | 0.12% | 145 |
|
|
2020
Q4 | $4.64M | Buy |
79,652
+2,351
| +3% | +$142K | 0.15% | 127 |
|
|
2020
Q3 | $4.88M | Buy |
77,301
+37,108
| +92% | +$2.57M | 0.2% | 99 |
|
|
2020
Q2 | $3.09M | Buy |
40,193
+3,387
| +9% | +$260K | 0.17% | 108 |
|
|
2020
Q1 | $2.75M | Sell |
36,806
-4,957
| -12% | -$343K | 0.17% | 110 |
|
|
2019
Q4 | $2.71M | Sell |
41,763
-16,302
| -28% | -$1.06M | 0.14% | 129 |
|
|
2019
Q3 | $3.68M | Sell |
58,065
-7,656
| -12% | -$500K | 0.22% | 104 |
|
|
2019
Q2 | $4.44M | Buy |
65,721
+27,856
| +74% | +$1.83M | 0.28% | 91 |
|
|
2019
Q1 | $2.46M | Sell |
37,865
-10,514
| -22% | -$699K | 0.17% | 143 |
|
|
2018
Q4 | $3.03M | Buy |
48,379
+2,023
| +4% | +$141K | 0.2% | 113 |
|
|
2018
Q3 | $3.58M | Sell |
46,356
-176
| -0.4% | -$13.3K | 0.25% | 108 |
|
|
2018
Q2 | $3.3M | Buy |
46,532
+2,630
| +6% | +$186K | 0.24% | 109 |
|
|
2018
Q1 | $3.31M | Sell |
43,902
-1,377
| -3% | -$109K | 0.25% | 102 |
|
|
2017
Q4 | $3.24M | Sell |
45,279
-4,286
| -9% | -$325K | 0.22% | 110 |
|
|
2017
Q3 | $4.02M | Buy |
49,565
+8,347
| +20% | +$638K | 0.28% | 81 |
|
|
2017
Q2 | $2.98M | Buy |
41,218
+92
| +0.2% | +$6.12K | 0.25% | 83 |
|
|
2017
Q1 | $2.79M | Buy |
+41,126
| New | +$2.89M | 0.23% | 85 |
|
Other funds holding GILD
VCM
VPM
Cerity Partners's GILD Position: Q1 2026 in Review
Cerity Partners increased its Gilead Sciences (GILD) stake by 0.01% in Q1 2026, buying an estimated $3.64K and bringing the position to 270,352 shares worth $37.7M. The position accounts for 0.05% of the portfolio, ranked #294.
Cerity Partners first reported a position in GILD in Q1 2017 and has held it in 37 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Cerity Partners held 270,352 shares of Gilead Sciences worth $37.7M as of Q1 2026.
- Cerity Partners bought 26 Gilead Sciences shares in Q1 2026, an estimated $3.64K.
- Gilead Sciences made up 0.05% of Cerity Partners's portfolio in Q1 2026, its #294 holding.
- Cerity Partners first reported a position in Gilead Sciences in Q1 2017 and has held it in 37 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.